Cargando…
Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
The toolbox for genetic engineering has quickly evolved from CRISPR/Cas9 to a myriad of different gene editors, each with promising properties and enormous clinical potential. However, a major challenge remains: delivering the CRISPR machinery to the nucleus of recipient cells in a nontoxic and effi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232299/ https://www.ncbi.nlm.nih.gov/pubmed/34198625 http://dx.doi.org/10.3390/pharmaceutics13060878 |
_version_ | 1783713608441528320 |
---|---|
author | Gustafsson, Oskar Rädler, Julia Roudi, Samantha Lehto, Tõnis Hällbrink, Mattias Lehto, Taavi Gupta, Dhanu Andaloussi, Samir EL Nordin, Joel Z. |
author_facet | Gustafsson, Oskar Rädler, Julia Roudi, Samantha Lehto, Tõnis Hällbrink, Mattias Lehto, Taavi Gupta, Dhanu Andaloussi, Samir EL Nordin, Joel Z. |
author_sort | Gustafsson, Oskar |
collection | PubMed |
description | The toolbox for genetic engineering has quickly evolved from CRISPR/Cas9 to a myriad of different gene editors, each with promising properties and enormous clinical potential. However, a major challenge remains: delivering the CRISPR machinery to the nucleus of recipient cells in a nontoxic and efficient manner. In this article, we repurpose an RNA-delivering cell-penetrating peptide, PepFect14 (PF14), to deliver Cas9 ribonucleoprotein (RNP). The RNP-CPP complex achieved high editing rates, e.g., up to 80% in HEK293T cells, while being active at low nanomolar ranges without any apparent signs of toxicity. The editing efficiency was similar to or better compared to the commercially available reagents RNAiMAX and CRISPRMax. The efficiency was thoroughly evaluated in reporter cells and wild-type cells by restriction enzyme digest and next-generation sequencing. Furthermore, the CPP-Cas9-RNP complexes were demonstrated to withstand storage at different conditions, including freeze-thaw cycles and freeze-drying, without a loss in editing efficiency. This CPP-based delivery strategy complements existing technologies and further opens up new opportunities for Cas9 RNP delivery, which can likely be extended to other gene editors in the future. |
format | Online Article Text |
id | pubmed-8232299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82322992021-06-26 Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP Gustafsson, Oskar Rädler, Julia Roudi, Samantha Lehto, Tõnis Hällbrink, Mattias Lehto, Taavi Gupta, Dhanu Andaloussi, Samir EL Nordin, Joel Z. Pharmaceutics Article The toolbox for genetic engineering has quickly evolved from CRISPR/Cas9 to a myriad of different gene editors, each with promising properties and enormous clinical potential. However, a major challenge remains: delivering the CRISPR machinery to the nucleus of recipient cells in a nontoxic and efficient manner. In this article, we repurpose an RNA-delivering cell-penetrating peptide, PepFect14 (PF14), to deliver Cas9 ribonucleoprotein (RNP). The RNP-CPP complex achieved high editing rates, e.g., up to 80% in HEK293T cells, while being active at low nanomolar ranges without any apparent signs of toxicity. The editing efficiency was similar to or better compared to the commercially available reagents RNAiMAX and CRISPRMax. The efficiency was thoroughly evaluated in reporter cells and wild-type cells by restriction enzyme digest and next-generation sequencing. Furthermore, the CPP-Cas9-RNP complexes were demonstrated to withstand storage at different conditions, including freeze-thaw cycles and freeze-drying, without a loss in editing efficiency. This CPP-based delivery strategy complements existing technologies and further opens up new opportunities for Cas9 RNP delivery, which can likely be extended to other gene editors in the future. MDPI 2021-06-14 /pmc/articles/PMC8232299/ /pubmed/34198625 http://dx.doi.org/10.3390/pharmaceutics13060878 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gustafsson, Oskar Rädler, Julia Roudi, Samantha Lehto, Tõnis Hällbrink, Mattias Lehto, Taavi Gupta, Dhanu Andaloussi, Samir EL Nordin, Joel Z. Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP |
title | Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP |
title_full | Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP |
title_fullStr | Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP |
title_full_unstemmed | Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP |
title_short | Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP |
title_sort | efficient peptide-mediated in vitro delivery of cas9 rnp |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232299/ https://www.ncbi.nlm.nih.gov/pubmed/34198625 http://dx.doi.org/10.3390/pharmaceutics13060878 |
work_keys_str_mv | AT gustafssonoskar efficientpeptidemediatedinvitrodeliveryofcas9rnp AT radlerjulia efficientpeptidemediatedinvitrodeliveryofcas9rnp AT roudisamantha efficientpeptidemediatedinvitrodeliveryofcas9rnp AT lehtotonis efficientpeptidemediatedinvitrodeliveryofcas9rnp AT hallbrinkmattias efficientpeptidemediatedinvitrodeliveryofcas9rnp AT lehtotaavi efficientpeptidemediatedinvitrodeliveryofcas9rnp AT guptadhanu efficientpeptidemediatedinvitrodeliveryofcas9rnp AT andaloussisamirel efficientpeptidemediatedinvitrodeliveryofcas9rnp AT nordinjoelz efficientpeptidemediatedinvitrodeliveryofcas9rnp |